Sanofi Consumer Healthcare India Limited has announced a significant change in its senior management. Chief Financial Officer (CFO) Narahari Naidu has tendered his resignation to pursue new career opportunities outside the organization.

Key Details of the Resignation

Company's Disclosure

The company, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has formally notified both the BSE Limited and the National Stock Exchange of India Limited about this change in senior management.

Naidu's Farewell

In his resignation email, Naidu expressed his gratitude towards the organization, stating, "It has been a privilege and an honour to serve this esteemed organisation. I am deeply grateful for the trust and support extended to me by each member of the Board, the senior leadership team, and my colleagues across the Company."

Impact and Next Steps

While the departure of a key executive like the CFO can be significant for any organization, Sanofi Consumer Healthcare India Limited has not yet announced a successor or interim arrangement for the CFO position. The company's board and management will likely be focusing on ensuring a smooth transition as they search for Naidu's replacement.

This development comes at a time when the pharmaceutical and healthcare sectors are navigating complex market dynamics. Investors and industry observers will be keenly watching how Sanofi Consumer Healthcare India Limited manages this transition and its potential impact on the company's financial strategy and performance.

As the company moves forward, stakeholders will be interested in any updates regarding the search for a new CFO and any potential shifts in financial strategy or management that may result from this change in leadership.

Sanofi Consumer Healthcare India Limited has announced the appointment of Mr. Narahari Naidu as its new Chief Financial Officer, effective August 4th, 2025. This strategic move comes as the company reports robust financial results for the second quarter of 2025.

New CFO Appointment

The Board of Directors, based on recommendations from the Nomination and Remuneration Committee and in consultation with the Audit Committee, has approved Mr. Naidu's appointment for a six-month term. Mr. Naidu brings over 14 years of diverse experience across healthcare/pharmaceuticals, manufacturing, and consulting sectors. His expertise spans:

• Finance & Accounts
• Procurement
• Investor Relations
• Mergers & Acquisitions
• Banking & Treasury
• IPO management

Prior to joining Sanofi Consumer Healthcare India, he served as Group CFO for entities operating across India, UK, and USA.

Strong Q2 Financial Performance

Alongside this key appointment, Sanofi Consumer Healthcare India has reported impressive financial results for the quarter ended June 30, 2025:

• Revenue from Operations: The company achieved a revenue of ₹2,209.00 million, marking a significant 28.21% year-on-year growth from ₹1,723.00 million in the same quarter last year.

• Profit After Tax: Net profit rose to ₹607.00 million, a 21.40% increase compared to ₹500.00 million in the previous quarter and a substantial 109.31% jump from ₹290.00 million in Q2 2024.

• Earnings Per Share: The Basic and Diluted EPS stood at ₹26.36, up from ₹21.69 in the previous quarter and ₹12.58 in Q2 2024.

Financial Highlights

Product Relaunch and Exceptional Items

The company has successfully relaunched Depura Adult and Combiflam Suspension during the recent quarters, following a voluntary recall in the previous year. This strategic move has contributed to the strong performance in Q2 2025.

Additionally, Sanofi Consumer Healthcare India recorded an exceptional gain of ₹66.00 million in Q2 2025 from reversing excess demerger-related provisions made in the previous year.

Outlook

With the appointment of Mr. Narahari Naidu as CFO and the strong financial performance in Q2 2025, Sanofi Consumer Healthcare India appears well-positioned for continued growth. The company's focus on relaunching key products and optimizing its financial structure suggests a strategic approach to enhancing shareholder value and market presence in the competitive pharmaceutical sector.

Investors and industry observers will be keenly watching how Mr. Naidu's extensive experience will contribute to Sanofi Consumer Healthcare India's financial strategies and growth initiatives in the coming months.